

#### 

#### **ABOUT CURIUM**

Curium is the world's largest nuclear medicine company following the union of two major North American and European suppliers. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.

The name 'Curium' honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named. The tagline 'Life Forward' represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.

Since our formation in 2017, we are pleased to report solid financial performance, which in turn supports significant investments to accelerate our growth through new product development and acquisitions. By reinvesting back into our business and products, we remain firmly focused on delivering vital products to over 14 million patients annually, who are in need of crucial diagnosis and treatment every day. In 2018, Curium became the first to offer 100% Low Enriched Uranium (LEU) generators in North America and has since expanded to supply LEU generators globally. We have secured a contract supporting Curium's long-term molybdenum-99 production. Through acquisition, we expanded our Positron Emission Tomography (PET) network world-wide, executed agreements for the development and distribution of new PET diagnostic agents and added new products to our portfolio. Another key achievement was our CEO, Renaud Dehareng, receiving prestigious recognition as one of USA's top CEOs in 2017, and being presented CEO Healthcare Award in 2018 and again in 2019. Over the last year, Curium has continued strong growth through acquisitions expanding its PET portfolio in the U.S. and Europe, launching new products, expanding on base products and achieving key milestones in new product development.

## Our History

We have been dedicated to serving the Nuclear Medicine industry since the 1960s. This long and proven heritage is something we continue to build upon.

Today, Curium is the world's leading nuclear medicine provider. We employ over 2,000 people globally, leveraging a deep scientific heritage, combined expertise, size and scale

## Our Values

Integrity, Commitment,
Collaboration: our core values
drive every aspect of our
behavior. It is our dedication to
these values that truly sets us
apart from the competition.

We use a two-pronged approach to help get the "job done". This involves team-work and various close internal and external partnerships. We strongly believe everyone deserves respect, dignity, and equality.

# Our Single Focus

It is one strong, singular focus that unifies our diverse group of industry experts — to develop, manufacture and supply Single-Photon Emission Computed Tomography (SPECT), PET and therapeutic radiopharmaceuticals to customers around the globe.

We are incredibly proud to say that we deliver diagnostic and therapeutic solutions for lifethreatening diseases to over 14 million patients a year. It's all part of our mission to give our clinicians superior solutions.

## Our Global Reach

Our vertically integrated radiopharmaceutical manufacturing networks are the largest the industry has to offer. They include: 1 molybdenum-99 processing facility, 4 manufacturing sites and over 40 PET & SPECT nuclear pharmacies across the United States and Europe.

Our unrivalled logistics and distribution network deliver exceptional service reliability that our customers can count on every day.



14 m
patients annually

6000+

global customers

2000

skilled employees

60+

countries

1

moly processing plant

4

manufacturing sites

40+

nuclear pharmacies

50+

products

## Our Products

We pride ourselves on our ability to deliver a steady supply of quality diagnostic and therapy solutions, with the highest standards of quality and safety assured at every stage. We are also committed to the development and launch of many more in the years to come.

Our portfolio of over 50 products offers both SPECT and PET solutions including generators, other hot products, cold kits, and auxiliary products to be used in the diagnosis and treatment of various debilitating diseases.

## Our Commitment

It is our exceptional service and industry dedication that enables us to build and foster long-term partnerships with our customers, something we continue to strive for.

We feel it is important to become a trusted partner to our customers—one that is a key contributor to helping patients and supporting future growth. We firmly believe this can only be achieved through the supply of high-quality products and services, enabling a better future for all.



### CURIUM GLOBAL HEADQUARTERS, LONDON

100 Pall Mall London SW1Y 5NQ United Kingdom

T: +44 208 051 9289

E: ContactLondonHQ@curiumpharma.com

W: curiumpharma.com

#### ^

### CURIUM GLOBAL HEADQUARTERS, PARIS

63 Avenue des Champs-Elysées 75008 Paris France

T: +33 1 53 57 73 31

E: ContactUs@curiumpharma.com

W: curiumpharma.com

### ~~~

# CURIUM NORTH AMERICA HEADQUARTERS

111 West Port Plaza
Suite 800
Saint Louis MO 6316

Saint Louis, MO 63146 United States

T: +1 314 384 8009

E: NuclearMedicine@curiumpharma.com

W: curiumpharma.com

#### $\wedge \wedge \wedge \wedge$

FOR ADDITIONAL INFORMATION VISIT OUR WEBSITE WWW.CURIUMPHARMA.COM



©2020 Curium US LLC. Curium™ is a trademark of a Curium company.